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Abstract 
Background and Objectives: Relatively little is known about the neuropsychological 
profiles of college students who misuse prescription stimulant medications. Methods: 
Data presented are from college students aged 18 to 28 years who misused prescription 
stimulants prescribed for attention-deficit/hyperactivity disorder and controls (no 
prescription stimulant misuse). Students were assessed neuropsychologically using the 
self-report Behavioral Rating Inventory of Executive Functioning (BRIEF-A), the 
Cambridge Automated Neuropsychological Test and Battery (CANTAB), and other tests 
of cognitive functioning. The analyses included 198 controls (age 20.7 ± 2.6 years) and 
100 prescription stimulant misusers (age 20.7 ± 1.7 years). Results: On the BRIEF-A, 
misusers were more likely than controls to endorse greater dysfunction on 8 of 12 
measures including Inhibition, Self Monitor, Initiation, Working Memory, and 
Plan/Organize, when adjusting for race and sex (all p’s <0.05). Similarly, when 
dichotomizing the BRIEF-A as abnormal (T score ≥ 65), misusers had more 
abnormalities on 5 of 9 subscales, as well as all major indices (p’s<0.05). Misusers also 
performed worse on several subtests of the CANTAB and standardized cognitive battery 
(p’s <0.05). A proxy of prescription stimulant misuse frequency was positively correlated 
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with greater executive dysfunction on the BRIEF-A. Discussion and Conclusions: These 
data demonstrate elevated risk for neuropsychological dysfunction among students who 
misuse prescription stimulants compared to non-misusing peers. The presence of ADHD 
contributed significantly to these cognitive findings. Students who misuse prescription 
stimulants should be screened for neuropsychological dysfunction. Scientific 
Significance: These data may better elucidate the neuropsychological profile of college-
aged prescription stimulant misusers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 Stimulant medications continue to be among the first line agents for attention-
deficit/hyperactivity disorder (ADHD) in older adolescents, and young adults.1 Many of 
the 4% to 5% of college students with ADHD2 receive stimulants,3 and stimulants are 
increasingly being diverted to those without a diagnosis of ADHD or a prescription.4,5 
Nonmedical use of prescription stimulants (e.g. use without a prescription) has risen 
accordingly, and has become a public health concern.6,7 
 Several studies have shed light on the context of prescription stimulant misuse. 
For instance, data from McCabe et al.8 suggest that stimulant misuse among high school 
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students is associated with higher rates of alcohol and drug use. Similarly, investigations 
in older populations provide evidence that prescription stimulant misusers are more likely 
to meet full criteria for a substance use disorder (SUD).9,10 In a 4-year prospective study, 
work by Arria et al.9 demonstrated that the escalation of substance use problems was 
related to both declining class attendance and academic performance, as well as 
subsequent stimulant misuse. This association between academic difficulties and 
nonmedical prescription stimulant use is an outcome widely corroborated by others.5,11-14  
Additional studies have shown that psychiatric disorders including depression14,15 
and ADHD16 may be related to stimulant misuse. Arria et al.17 reported significantly 
higher levels of ADHD symptoms among individuals with persistent, nonmedical 
prescription stimulant use throughout college, compared to both non-users of drugs or 
persistent marijuana users. Similarly, using blinded structured interviews, we recently 
reported a two-fold risk for broad ADHD—inclusion of both subthreshold and threshold 
symptoms—associated with stimulant misuse in a college sample.18  
These emerging data show compelling associations between stimulant misuse, 
ADHD symptomatology, SUD, academic decline, and other categorical psychiatric 
diagnoses.5,9,16,19 Prior work has focused on the potential cognitive enhancement of 
stimulants among healthy adults, but there is a paucity of data on the occurrence and 
nature of cognitive dysfunction in prescription stimulant misusers. Despite speculation of 
“self medication” associated with prescription stimulant misuse,20 relatively few data 
exist on the subjective and objective neuropsychological functioningparticularly 
executive functioningin traditional college-aged students who report misusing 
stimulants. One study (N=305) in a college setting showed a positive association between 
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self-reported executive dysfunction and prescription stimulant misuse.21 While useful, 
this thesis on a small sample of actual stimulant misusers (N=58) necessitates replication 
with larger samples and more sophisticated definitions for neuropsychological 
functioning.   
To this end, we now report on a controlled study of stimulant misuse in college 
students. The current investigation represents a planned, primary analysis of cognitive 
functioning among prescription stimulant misusing college students compared to their 
non-misusing peers. Based on past findings of higher ADHD rates17,18,20 and lower 
academic performance5,9,16 in stimulant misusers, we hypothesized that stimulant 
misusers would endorse higher rates of both cognitive dysfunction in general and 
executive dysfunction specifically, compared to college students who do not misuse 
stimulants. Furthermore, we hypothesized that stimulant misusers would exhibit greater 
deficits on both subjective, self-report measures and objective tests of neuropsychological 
functioning. We also sought to replicate findings of lower academic performance in 
misusers compared to their non-misusing peers.  
METHODS 
 
Details of the study are presented elsewhere.18 Briefly, we recruited 100 subjects 
who were not currently receiving prescription stimulants therapeutically, but endorsed 
misusing a stimulant medication (misusers), and 200 subjects who similarly were not 
being treated with stimulant medication, and had never misused prescription stimulants 
(controls). A prior diagnosis of ADHD was not exclusionary for either group. For the 
purpose of this report, stimulant misuse was defined as the procurement and illicit use of 
another individual’s prescription stimulant medication, or past misuse of one’s own legal 
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prescription (e.g. using more than prescribed). Misusers and controls were categorized 
appropriately following a pre-screening questionnaire, in addition to specific prompts on 
the MGH Medication Misuse Assessment that queried for misuse of a legal stimulant 
prescription, or misuse of another individual’s stimulant prescription. Of note, only a 
single incident of misuse was needed to categorize an individual as a misuser. 
Additionally, we were only concerned with those stimulants with FDA indications for 
ADHD, and did not investigate the misuse of modafinil, armodafinil, methamphetamine 
or other sympathomimetic amines (e.g. cocaine, MDMA) or the misuse of non-stimulant 
ADHD medications.22  
Subjects from both misuse and control groups were full-time undergraduate 
college students (18 and 28 years) in the Boston metropolitan area recruited by way of 
internet advertisements (e.g., craigslist.com, myspace.com, etc.). Eligible individuals 
were contacted to complete a direct interview and self-report questionnaires. All subjects 
completed an informed consent to participate in the study. We obtained a federal release 
of confidentiality, and all aspects of the study were approved by the institutional review 
board. 
Assessments 
 
Neuropsychological Functioning  
 
To assess clinical evidence of executive functioning, we used the Behavior Rating 
Inventory for Executive Function-Adult Version (BRIEF-A).23 The BRIEF-A is a 
standardized self-report measure for adults 18-90 years that captures the behavioral 
manifestations of executive dysfunction across 9 different subscales: Inhibit, Shift, 
Emotional Control, Self Monitor, Initiate, Working Memory, Plan/Organize, Task 
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Monitor, and Organization of Materials. The first 4 of the aforementioned 9 scales 
comprise the higher-level Behavioral Regulation Index (BRI), which is a measure of an 
individual’s ability to appropriately regulate behavioral and emotional responses. The 
remaining 5 scales comprise the Metacognition Index (MI), which assesses an 
individual’s effective use of planning and organization to problem solve. When 
combined, the BRI and MI map onto the Global Executive Composite (GEC). Higher 
scores on any of the 9 subscales, or the indices, are indicative of more severe executive 
dysfunction.   
The BRIEF-A is a self-report scale comprised of 75 questions that are answered 
with a “Never,” “Sometimes,” or “Often” response. For example, the Self-Monitor 
subscale assesses aspects of interpersonal and social awareness and prompts the reader to 
answer how frequently he/she talks at inappropriate times, has difficulty reading others’ 
feelings, doesn’t understand why others might be upset, or says things without thinking, 
etc. Although there are 9 subscales, questions are interspersed throughout and lack a 
visible demarcation indicating which subscale a question belongs to (e.g. Self-Monitor 
draws from questions: 13, 23, 37, 50, 64, 70). The BRIEF-A has demonstrated reliability 
and validity across the major indices and composite subscales when assessing executive 
functioning in college students.24  
Neuropsychological Assessment 
 
 For our neuropsychological assessment battery, we used The Cambridge 
Neuropsychological Test Automated Battery (CANTAB),25 which is a computerized test 
system that assesses a range of executive functioning abilities: decision making and 
response control, attention, visual memory, semantic/verbal memory, and cognitive 
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flexibility and planning. The CANTAB has demonstrated reliability when assessing 
cognitive functioning in substance-using patients.26 Subtests included the following: 
Spatial Working Memory (SWM), Verbal Recognition Memory (VRM), Stockings of 
Cambridge (SOC), Intra-Extra Dimensional Set Shifting (IED), Rapid Visual Information 
Processing (RVP), Affective Go/No-go (AGN), and Reaction Time (RTI). 
 
For IQ, subjects completed the Wechsler Abbreviated Scale of Intelligence (WASI-II):27 
Vocabulary and Matrix Reasoning. Additional cognitive tests included the Wechsler 
Adult Intelligence Scale (WAIS-IV),28 Wide Range Achievement Test (WRAT-III 
Math),29 the Test of Word Reading Efficiency (TOWRE-II),30 and the Delis-Kaplan 
Executive Functions Scale (DKEFS).31 In total, administration time of the BRIEF-A, 
CANTAB, IQ testing, structured interview, and other self-report measures averaged 
between two and a half to four hours.  
 
Frequency of Stimulant Misuse 
Due to the heterogeneity of the misuse group (i.e. some individuals may have only 
misused once or twice, while others may have misused many times) we were interested in 
comparing neuropsychological functioning of misusers with varying frequencies of 
stimulant misuse. Unfortunately, we did not have a question that specifically queried for 
lifetime frequency of stimulant misuse across our entire misuse sample. Instead, we 
derived estimated frequency of stimulant misuse using a single item from the previously 
described MGH Medication Misuse and Diversion Assessment.18,32 The single item read; 
“On how many occasions have you bought or traded prescription ADHD medication that 
was not prescribed to you?” Subjects were demarcated based on lifetime frequency of 
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misuse categorized as either: 1-5 times, 6-20 times, or 20+ times. 
 
Statistical Analyses 
 
We used the Student’s t-test for continuous outcomes, the Wilcoxon rank-sum 
tests for SES, and Pearson’s χ2 for binary outcomes. Fisher’s exact test was used in the 
event of small numbers. Linear and logistic regression were used to analyze the BRIEF-A 
and CANTAB. To determine whether sex affected the relationship between misusers and 
the endorsement of psychiatric disorders and SUD, we included the interaction term, 
misuse status-by-sex, in all models. If the interaction was not significant, we removed it 
from the analyses and collapsed the results; if it was significant we reported the results by 
sex. All statistical analyses were conducted using Stata 12.0. All tests were two-tailed 
with an alpha level set at 0.05 unless noted otherwise. Data are presented as mean ± 
standard deviation (SD) unless otherwise specified. 
 
RESULTS 
 
Clinical characteristics of the sample 
  
As described previously,18 our final sample included 100 stimulant misusers (age 
20.7 ± 1.7 years) and 198 controls (age 20.7 ± 2.6 years)—a total of 2 controls from the 
originally recruited 200 were dropped a priori from the analysis due to incomplete data. 
There were no significant differences between misusers and controls in age, 
socioeconomic status (SES; 2.0 ± 1.0 vs. 1.9 ± 0.9; z=-0.58; p=0.57), or gender (47% vs. 
41% male; χ 2 =0.84; p=0.36). There were also no significant differences between 
misusers and controls regarding the repeating of a grade, special class accommodations, 
or extra help. We did find however, that misusers were more likely to be Caucasian than 
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controls (84% vs. 68%; χ 2 =8.53; p=0.03). As a result, we adjusted for race across all 
analyses.  
 
Clinical evidence of executive functioning (BRIEF-A) 
 
Insert Table 1 
 
We first examined T-scores on the self-reported BRIEF-A, and found that 
stimulant misusers were more likely to endorse higher scores indicative of greater 
dysfunction in executive cognitive operations. Specifically, misusers endorsed a higher 
GEC (p=0.02) when adjusting for race and sex (Table 1A). Misusers also manifested 
more dysfunction than controls on the BRI (p=0.03) and MI (p=0.02). Of the nine 
subscales that contribute to the GEC, misusers scored higher than controls on the 
following: Inhibition, Self Monitor, Initiation, Working Memory, and Plan/Organize (all 
p values <0.05). When ADHD was included in the model, two indices (BRI, GEC) and 
three subscales (Self-Monitor, Initiation, Plan/Organize) lost statistical significance.  
We next examined clinically relevant abnormalities on the BRIEF-A (i.e. T scores 
≥ 65). As seen in Table 1B, misusers were more likely to manifest clinical evidence of 
executive dysfunction than controls in multiple domains. More misusers than controls 
endorsed a T score ≥ 65 for the overall GEC, BRI, and MI (all p’s ≤0.02). Upon 
examination of the nine BRIEF-A subscales, more misusers than controls had clinically 
and statistically significant abnormalities (T score ≥ 65) for Inhibition, Initiation, 
Working Memory, Plan/Organize, and Task Monitor (all p<0.05). When ADHD was 
included in the model, two indices (BRI, GEC) and two subscales (Working Memory, 
Task Monitor) on the BRIEF-A lost statistical significance. 
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Objective neuropsychological functioning (CANTAB) 
 
Insert Table 2 
We utilized the CANTAB to examine objective neuropsychological differences 
between stimulant misusers and controls. For the CANTAB, we found a significant sex 
interaction effect for Stockings of Cambridge (SOC): problems solved in minimum 
moves and Rapid Visual Information Processing (RVP) A’ (Table 2). For the SOC, male 
misusers performed significantly worse compared to male controls, when adjusting for 
race (p=0.046). When ADHD was added to the model, this subtest lost significance. 
Similarly, when adjusting for race, male misusers performed worse than male controls on 
the RVP test (p=0.007) and significance remained after ADHD was added to the model.  
Analyses focusing on the remaining tasks of the CANTAB revealed that misusers, 
compared to controls, were more likely to have a higher score for the median correct 
latency variable of the Affective Go/No-Go (AGN), when adjusting for race and gender  
(p=0.01). We found no other significant associations (all p values >0.05).  
 
Additional cognitive battery 
 
Insert Table 3 
 
In addition to the CANTAB, a cognitive battery drawing from various 
standardized assessments was used to objectively assess neuropsychological performance 
(Table 3). There were no significant differences between misusers and controls regarding 
Full Scale IQ; however, misusers were more likely to score lower on the Digit Span 
(p=0.03), and Letter Number Sequencing (p=0.01) subtests, as well as the cumulative 
Working Memory index of the WAIS-IV, when adjusting for race and sex. All of the 
aforementioned differences on the WAIS-IV remained statistically significant after 
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ADHD was added to the model. We found no other significant associations on the 
remaining subtests of the WRAT-III, TOWRE-II, and DKEFS (all p values >0.05).  
 
Frequency of Stimulant Misuse 
Insert Table 4 
We further examined a subset of 83 misusers who were divided into three groups based 
on lifetime frequency of buying or trading prescription stimulants: 1-5 times (N=53), 6-
20 times (N=23), or 20+ times (N=7). There was a significant, positive correlation 
between greater frequency of buying or trading prescription stimulants and self-reported 
executive dysfunction on all subscales and indices of the BRIEF-A (p <0.05) (Table 4), 
excluding Task Monitor.  
 
DISCUSSION 
 
Our current data support our hypothesis that despite similar intelligence, college-
aged stimulant misusers have more evidence of neuropsychological dysfunction in 
general, and clinical executive dysfunction specifically, compared to their non-misusing 
peers. The amount of misuse appears connected to the severity of executive functioning 
difficulties. Due to the cross-sectional nature of the sample and high rates of confounders 
such as ADHD and SUDs – independently linked to neuropsychological dysfunction33,34 
– the directionality or mechanism(s) of risk of cognitive deficits are outside of the scope 
of this study and need to be further examined.  
Our finding of more executive dysfunction in stimulant misusers compared to 
controls supports prior work conducted with a smaller sample,21 in addition to extending 
the work of others who have shown ADHD symptomatology, academic decline and 
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performance issues related to stimulant misuse.5,9,16,18 In fact, the two-fold risk for broad 
ADHD among misusers previously reported in this sample (misusers 27% vs. controls 
16%), combined with the loss of significance for a range of subtests when covarying by 
ADHD, suggests that ADHD symptomatology contributed substantially to the 
neuropsychological dysfunction among misusers. Irrespective of the origin of the 
observed neuropsychological deficits (e.g. due to ADHD, SUD, other psychopathology) 
these data are among the first to report simultaneously on subjectively and objectively 
derived cognitive dysfunction in young adults who engage in the misuse of prescription 
stimulants used for the treatment of ADHD.  
Self-reported levels of dimensionally rated executive dysfunction were 
significantly greater among stimulant misusers compared to controls on the three major 
indices of the BRIEF-A (i.e. GEC, BRI, and MI), and five of the nine subscales (Table 
1A). Elevated scores on the BRI for this sample suggest stimulant misusers are more 
likely to suffer from an impaired ability to both monitor the self and situation for what are 
considered to be acceptable social behaviors and to inhibit impulsive reactions. Elevated 
scores on the MI, which remained significant even when covarying by ADHD, suggest 
that when stimulant misusers are presented with a problem, they are less adept at 
maintaining and organizing information in working memory, strategically planning and 
executing a response, and making necessary changes based on the outcome. The 
breakdown of stimulant misusers versus controls with abnormal threshold of executive 
dysfunction (e.g., T-scores ≥ 65) provides further insight into the self-perceived 
differential functioning between the two groups. Misusers not only scored dimensionally 
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higher than controls on the aforementioned scales (Table 1A), but were also more likely 
to exhibit dysfunction at severe, clinically relevant levels (T ≥ 65) (Table 1B).  
Although we found relatively fewer major differences between misusers and 
controls on the objective CANTAB and IQ/cognitive tests, several measures were 
significant. For instance, in SOC in males, spatial planning difficulties were noted that 
have been related to frontal lobe dysfunction.25,35,36 Prior work has linked frontal lobe 
dysfunction to cognitively impaired decision-making, response inhibition, planning, and 
memory.37,38 Other objective findings indicated a decreased capacity for vigilance and 
sustained attention (male misusers), processing biases, and working memory difficulties 
in misusers– also substantiated by self report on the BRIEF-A. These findings have been 
linked to neuropsychological dysfunction, SUD,39 risk for substance use in 
adolescence,40,41 and affective disorders.42,43  
Similar to Rabiner and colleagues,16 we previously reported higher rates of 
ADHD among stimulant misusers in this sample.18 The current data further suggest that 
misusers are at higher risk for deficits in attention and executive functioning – both of 
which have been independently related to SUD and academic underachievement in older 
adolescents and young adults.44-46 While the directionality of the association remains 
unclear in our study, executive dysfunction appears linked to stimulant misuse. Due to 
the high rates of alcohol and drug use disorders among stimulant misusers in the current 
sample,18 SUD may be contributory in part to the observed neuropsychological 
dysfunction. Further studies might aim to better elucidate the relative contributions of 
ADHD and SUD to the neuropsychological dysfunction of college-aged stimulant 
misusers.  
Au
tho
r M
an
us
cri
pt
We speculate that the cognitive impairment in this population likely represents a 
preexisting condition that misusers may attempt to reconcile by misusing prescription 
stimulants. The positive correlation in the current report between our proxy of stimulant 
misuse frequency and level of executive dysfunction, appears to support this supposition. 
Given the inherent pressures to perform academically in college, it is not altogether 
surprising that the nonmedical use of prescription stimulants represents one of the few 
substance use behaviors that is more prevalent among traditional-age college students 
relative to their same-age young adult peers not attending college.6 Our findings, in 
conjunction with the literature, lend credibility to the notion that stimulant misusing 
college students may be self-medicating attentional difficulties, executive dysfunction, 
and academic impairment.  
There are a number of limitations in the current report. Although the 
overwhelming majority of findings consistently trended in the direction predicted by our 
hypotheses, the risk for Type I error must be acknowledged due to the number of 
(sub)tests on the BRIEF-A, CANTAB and our cognitive battery. Statistical corrections 
were not conducted because of the cross-sectional nature of the study and in order to 
prevent the introduction of Type II error. The heterogeneous nature of our misuse group 
(i.e. single misuse and 20+ incidents of lifetime misuse grouped together) likely resulted 
in an underestimation of effect sizes. Students were derived from the metropolitan Boston 
area and may not generalize to other regions. While the overall sample size was modest 
(N=298), the cell sizes in specific groups were relatively small, thus limiting our Power. 
Since we relied on self-report for some of our measures, our subjects may not have 
completed their questionnaires fully, and/or may have underreported their pathology. 
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Additionally, we did not instruct misusers to abstain from nonmedical use of stimulants 
on the day of neuropsychological testing, although a minority of misusers reported 
current nonmedical use of prescription stimulants by way of self-report and scheduled 
interview. We did not account for the higher risk for ADHD in misusers versus controls; 
however, for these analyses, we were focused on cognitive dysfunction relative to 
stimulant misuse status and not the role of ADHD. Our proxy of frequency of stimulant 
misuse was based on a single item from a questionnaire that indirectly evaluated this 
issue. Lastly, our data are cross-sectional, and as such, are associative in nature.  
 Despite these limitations, the current controlled study provides new information 
on the high rates of neuropsychological dysfunction in general, and executive dysfunction 
more specifically, in college students who misuse prescription stimulant medications. Our 
findings add to previous work linking high rates of ADHD and executive dysfunction to 
misuse of prescription stimulants, and highlight the need to clinically and scientifically 
further assess neuropsychological functioning in college students who misuse 
prescription stimulant medications.  
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Table 1: Evaluation of clinically significant executive functioning on the Behavior Rating Inventory of 
Executive Function-Adult Version (BRIEF-A) for prescription stimulant misusers versus controls 
A.  BRIEF-A (continuous)  
 
 Misusers (N=100) Controls (N=197)  
Subscale T Score ± SD T Score ± SD Statistics 
55.3 ± 12.2 50.9 ± 10.6 beta: 4.5; 95% Confidence Interval (CI): 1.7, 7.2; p=0.001 * 
51.7 ± 11.3 50.8 ± 10.3 beta: 1.1; 95% CI: -1.5, 3.7; p=0.4  
Emotional Control 48.4 ± 10.5 47.6 ± 10.3 beta: 1.3; 95% CI: -1.2, 3.7; p=0.3  
 49.3 ± 10.7 46.3 ± 9.9 beta: 3.2; 95% CI: 0.7, 5.7; p=0.01 ψ 
54 ± 12.2  51.4 ± 10.5 beta: 2.8; 95% CI: 0.1, 5.5; p=0.04 ψ 
Working Memory 56 ±12.5 52.8 ± 10.7 beta: 3.6; 95% CI: 0.8, 6.4;p=0.01* 
Plan/Organize 54.1 ± 12.3 50.6 ± 10.3 beta: 3.3; 95% CI: 0.6, 6.0; p=0.02 ψ 
Task Monitor 55.6 ± 12.3 53 ± 11.1 beta: 2.8; 95% CI: -0.07, 5.6; p=0.056  
Organization of Material 52.5 ± 11.6 50.1 ± 10.9 beta: 1.9; 95% CI: -0.8, 4.6; p=0.18  
Index    
Metacognition (MI) 52.5 ± 10.5 49.6 ± 8.9 beta: 2.9; 95% CI: 0.6, 5.2; p=0.02 * 
Behavioral Regulation (BRI) 49.1 ± 9.2 47.0 ± 8.0 beta: 2.2; 95% CI: 0.2, 4.3; p=0.03 ψ 
Global Executive Composite (GEC) 50.9 ± 9.9 48.3 ± 8.4 beta: 2.6; 95% CI: 0.4, 4.8; p=0.02 ψ 
11 subject did not complete the BRIEF; ψp-value >0.05 when ADHD was included in the model; *p-value 
<0.05 when ADHD was included in the model 
 
B.  BRIEF-A (dichotomous, >=65)1 
 
 Misusers 
(N=100) 
Controls 
(N=197)  
Subscale N (%) N (%) Statistics 
22 (22) 19 (10) Odds Ratio (OR)=2.7; 95% Confidence Interval (CI): 1.4, 5.3; p=0.005* 
14 (14) 18 (9) OR: 1.8; 95% CI: 0.8, 3.8; p=0.15  
Emotional Control 10 (10) 19 (10) OR: 1.1; 95% CI: 0.5, 2.5; p=0.8  
 10 (10) 10 (5) OR: 2.1; 95% CI: 0.8, 5.4; p=0.1  
21 (21) 19 (10) OR: 2.5; 95% CI: 1.3, 5.1; p=0.008* 
Working Memory 24 (24) 31 (16) OR: 1.9; 95% CI: 1.01, 3.5; p=0.05 ψ 
Plan/Organize 25 (25) 20 (10) OR: 2.7; 95% CI: 1.4, 5.2; p=0.003* 
Monitor 22 (22) 26 (13) OR: 1.9; 95% CI: 1.0, 3.6; p=0.05 ψ 
Organization of Material 17 (17) 21 (11) OR: 1.6; 95% CI: 0.8, 3.2; p=0.2  
Index    
Metacognition (MI) 14 (14) 7 (4) OR: 4.7; 95% CI: 1.8, 12.4; p=0.002* 
Behavioral Regulation (BRI) 8 (8) 4 (2) OR=4.9; 95% CI: 1.4, 17.5; p=0.01 ψ 
Global Executive Composite (GEC) 10 (10) 6 (3) OR: 3.4; 95% CI: 1.2, 9.8; p=0.02 ψ 
11 subject did not complete the BRIEF; ψp-value >0.05 when ADHD was included in the model; *p-value 
<0.05 when ADHD was included in the model 
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Table 2.  Comparative performance of prescription stimulant misusers versus controls on the Cambridge 
Neuropsychological Test Automated Battery (CANTAB)1 
 
1One subject was dropped from the analysis due to a missing test 
2Two subjects were dropped due to scores outside of the range of normal 
3Two subjects were dropped due to scores outside of the range of normal 
4Ten subjects were dropped due to scores outside of the range of normal  
ψp-value>0.05 when ADHD included in the model 
*p-value<0.05 when ADHD included in the model 
 
 
 
Misusers 
N=100 
Controls 
N=197 
Statistics 
 Mean ± SD Mean ± SD  
Verbal Recognition Memory (VRM)    
Free recall – total correct (immediate) 7.1 ± 1.9 7.4 ± 2 beta: -0.3; 95% Confidence Interval (CI): p=0.16  
Recognition – total correct (immediate)  23.0 ± 1.1 23.2 ± 1.1 beta: -0.2; 95% CI: -0.5, 0.1; p=0.16
Recognition – total correct (delayed) 22.7 ± 1.5 22.8 ± 1.5 beta: -0.1; 95% CI:-0.5, 0.2; p=0.44
Spatial Working Memory (SWM)2    
Between errors 16.2 ± 12.9 15.4 ± 14.3 beta: 2.4; 95% CI: -0.9, 5.6; p=0.2
Between errors z score 0.9  ± 0.5 0.9  ± 0.6 beta: -0.8; 95% CI: -0.2, 0.5; p=0.2
Strategy 27.8 ± 8.3 28.8 ± 7.1 beta: -0.4; 95% CI: -2.3, 1.4; p=0.6
Strategy z score 0.8  ± 0.9 0.7 ± 1.0  beta: -0.5; 95% CI: -0.3, 0.2; p=0.7
Stockings of Cambridge (SOC)    
Male    
Problems solved in minimum moves 9.5 ± 1.7 10.1 ± 1.7 beta: -0.6; 95% CI: -1.3, -0.01; p=0.046
Problems solved in minimum moves z score 0.7 ± 0.8 1.0 ± 0.8 beta: -0.3; 95% CI: -0.6, -0.005; p=0.046
Female    
Problems solved in minimum moves 9.5 ± 1.8 9.0 ± 2.0 beta: 0.5; 95% CI: -0.1, 1.1; p=0.13
Problems solved in minimum moves z score 0.7 ± 0.9 0.4 ± 1.0 beta: 0.3; 95% CI: -0.7, 0.6; p=0.13
Intra-Extra Dimensional Set Shift (IED)    
Total errors (adjusted) 20.3 ± 18.1 21.7 ± 24.7 beta: 0.03; 95% CI: -5.5, 5.6; p=1.0
Total errors (adjusted) z score 0.3 ± 0.5 0.3 ± 0.7 beta: -0.0; 95% CI: -0.2, 0.2; p=1.0
Affective Go/No-Go (AGN)3    
Correct latency – median – positive 502 ± 63.4 485.2 ± 58 beta: 18.7; 95% CI: 3.8, 33.6; p=0.01
Correct latency – median – negative 503.4 ± 58.2 493.3 ± 62.8 beta: 12; 95% CI: -3.4, 27.4; p=0.13
Rapid Visual Information Processing 
(RVP)   
 
Response latency – median 397.2 ± 70.3 402.9 ± 94 beta: -3.6; 95% CI: -25.1, 18; p=0.7
Response latency – median z score 1.0 ± 0.7 0.9 ± 0.9 beta: 0.04; 95% CI: -0.2, 0.2; p=0.7
Male    
A’4 0.89 ± 0.1 0.94± 0.05 beta: -0.05; 95% CI: -0.09, -0.01; p=0.007
A’ z score 0.12 ± 0.9 0.37 ± 0.9 beta: -0.3; 95% CI: -0.7, -0.03; p=0.04
Female    
A’3 0.92 ± 0.07 0.93 ± 0.05 beta: -0.005; 95% CI: -0.02, 0.01; p=0.59
A’ z score 0.24 ± 0.7 0.18 ± 0.9 beta: 0.05; 95% CI: -0.2, 0.3; p=0.7
Reaction Time (RTI)    
Five-choice reaction time – median 330.7 ± 79.2 327.5 ± 46.7 beta: 6.6; 95% CI: -7.9, 21.1; p=0.4
Five-choice reaction time – median z score 0.5 ± 1.3 0.6 ± 0.8 beta: -0.1; 95% CI: -0.3, 0.1; p=0.4
Simple reaction time – median 306.8 ± 66.4 304.2 ± 50 beta: 5.1; 95% CI: -8.5, 18.7; p=0.5
Simple reaction time – median z score 0.3 ± 0.8 0.3 ± 0.6 beta: -0.6; 95% CI: -0.2, 0.1; p=0.5
Five-choice error score – all 0.1 ± 0.4 0.1 ± 0.4 beta: 0.005; 95% CI: -0.1, 0.1; p=0.9
Simple error score – all 0.2 ± 1.0 0.2 ± 0.6 beta: -0.01; 95% CI: -0.2, 0.2; p=0.9
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Table 3. Scaled scores denoting cognitive functioning on the Wechsler Abbreviated 
Scale of Intelligence (WASI-II) and Wechsler Adult Intelligence Scale (WAIS-IV) for 
stimulant misusers versus controls.  
 
 
 
ψp-value>0.05 when ADHD was included in the model 
*p-value<0.05 when ADHD was included in the model 
 Misusers (N=100) Controls 
(N=198) 
Test statistics, p-value
WASI-II Mean ± SD Mean ± SD  
Vocabulary Scaled Score 12.9 ± 2.1 13.2 ± 2.5 beta: -0.5; 95% Confidence Interval (CI): 
-1.1, 0.09; p=0.10  
Matrix Scaled Score 11.7 ± 1.8 11.5 ± 2.2 beta: 0.1; 95% CI: -0.4, 0.6; p=0.
Full Scale IQ 113 ± 8.9 113.5 ± 11.2 beta: -1.1; 95% CI: -3.7, 1.4; p=0.
WAIS-IV    
Digit Span Scaled Score 10.8 ± 2.5 11.5 ± 3.0 beta: -0.8; 95% CI:-1.5, -0.09; p=0.
Arithmetic Scaled Score 12.1 ± 2.3 12.1 ± 2.5 beta: -0.1; 95% CI: -0.7, 0.4; p=0.
Letter Number Scaled Score 11.2 ± 2.3 11.9 ± 2.9 beta: -0.9; 95% CI: -1.5, -0.2; p=0.01
Digit Symbol Scaled Score 11.1 ± 2.6 11.5 ± 2.9 beta: -0.5; 95% CI: -1.2, 0.1; p=0.1
Symbol Search Scaled Score 12.7 ± 2.5 12.8 ± 3.2 beta: -0.2; 95% CI: -0.9, 0.5; p=0.64
Working Memory 107.7 ± 11.3 110.7 ± 14.1 beta: -3.9; 95% CI: -7.1, -0.7; p=0.02
Processing Speed 110.6 ± 12.9 111.9 ± 15.7 beta: -1.9, 95% CI: -5.5, 1.6; p=0.3
 
 
 
Table 4. Relationship between frequency of buying/trading prescription stimulants 
and clinical executive functioning measured by the Behavior Rating Inventory of 
Executive Functioning-Adult Version (BRIEF-A). 
 
 1-5 Times 
(N=53) 
6-20 times 
(N=23) 
20+ Times 
(N=7) 
F statistic, p-value 
Subscale 
Inhibition 53.4 ± 11.3 56.7 ± 12.6 65.3 ± 13.6 F=3.3; p=0.041 
Shifting 50.5 ± 9.2 51.3 ± 12.5 61.4 ± 14.9 F=3.2; p=0.046 
Emotional Control 45.5 ± 8.2 52.4 ± 12.7 56.1 ± 14.6 F=6.0; p=0.004 
Self Monitor 48.3 ± 9.1 51 ± 12.1 60.7 ± 11.8 F=4.7; p=0.01 
Initiation 51.0 ± 9.9 54.6 ± 12.6  68.7 ± 11.8 F=8.4; p<0.001 
Working Memory 54.9 ± 11.7 55.1 ±12.5 66.9 ± 13.4 F=3.1; p=0.049 
Plan/Organize 51.4 ± 9.8 54.0 ± 13.2 69.4 ± 11.2 F=8.4; p<0.001 
Task Monitor 54.7 ± 11.6 55.0 ± 12.9 63.6 ± 13.5 F=1.7; p=0.2 
Organization of Material 50.8 ± 11.8 53.3 ± 9.9 63.1 ± 9.1 F=3.9; p=0.02 
Index 
Metacognition  50.5 ± 9.1 52.4 ± 10.5 64.7 ± 9.4 F=6.9; p=0.002 
Behavioral Regulation  47.0 ± 7.4 51.2 ± 10.5 58.4 ± 12.3 F=6.1; p=0.004 
Global Executive Composite  48.9 ± 8.3 51.7 ± 10.1 62.4 ± 11.3 F=7.1; p=0.002 
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Among misusers only (N=83) who answered the prompt, “On how many occasions have you 
bought or traded prescription ADHD medication that was not prescribed to you?” a linear 
association between prescription stimulant diversion frequency and T-score on the BRIEF-A 
subscales was observed 
 
 
 
 
 
 
